Applied Genetic Technologies Corp. (NASDAQ:AGTC) Director Ivana Magovcevic acquired 3,000 shares of Applied Genetic Technologies Corp. stock in a transaction that occurred on Wednesday, November 16th. The shares were purchased at an average price of $9.63 per share, for a total transaction of $28,890.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $28,890. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) opened at 10.05 on Monday. The firm has a market capitalization of $181.42 million, a P/E ratio of 15.98 and a beta of 1.54. Applied Genetic Technologies Corp. has a one year low of $6.35 and a one year high of $21.43. The firm’s 50-day moving average price is $8.66 and its 200 day moving average price is $12.83.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last issued its quarterly earnings data on Tuesday, November 8th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.28. Applied Genetic Technologies Corp. had a return on equity of 10.56% and a net margin of 23.63%. The company had revenue of $11.80 million for the quarter, compared to the consensus estimate of $10.21 million. During the same quarter last year, the business posted ($0.53) earnings per share. The firm’s revenue was up 6.8% compared to the same quarter last year. On average, equities analysts anticipate that Applied Genetic Technologies Corp. will post $0.05 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of AGTC. Schroder Investment Management Group acquired a new stake in shares of Applied Genetic Technologies Corp. during the second quarter worth about $976,000. Emerald Acquisition Ltd. acquired a new stake in shares of Applied Genetic Technologies Corp. during the second quarter worth about $1,782,000. DUPONT CAPITAL MANAGEMENT Corp acquired a new stake in shares of Applied Genetic Technologies Corp. during the second quarter worth about $516,000. Globeflex Capital L P acquired a new stake in shares of Applied Genetic Technologies Corp. during the second quarter worth about $997,000. Finally, Acrospire Investment Management LLC increased its stake in shares of Applied Genetic Technologies Corp. by 13.1% in the second quarter. Acrospire Investment Management LLC now owns 15,943 shares of the company’s stock worth $225,000 after buying an additional 1,842 shares during the period. Institutional investors own 57.05% of the company’s stock.

A number of equities research analysts recently weighed in on AGTC shares. Zacks Investment Research upgraded Applied Genetic Technologies Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Tuesday, October 11th. Janney Montgomery Scott upgraded Applied Genetic Technologies Corp. from a “sell” rating to a “neutral” rating and set a $11.00 price objective on the stock in a research report on Monday, September 26th. Stifel Nicolaus reduced their price objective on Applied Genetic Technologies Corp. from $29.00 to $24.00 and set a “buy” rating on the stock in a research report on Tuesday, September 13th. Roth Capital restated a “neutral” rating and set a $12.00 price objective on shares of Applied Genetic Technologies Corp. in a research report on Sunday, October 23rd. Finally, Wells Fargo & Co. lowered Applied Genetic Technologies Corp. from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 13th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $17.03.

About Applied Genetic Technologies Corp.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

5 Day Chart for NASDAQ:AGTC

Receive News & Stock Ratings for Applied Genetic Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corp. and related stocks with our FREE daily email newsletter.